News

Updated data were presented at the ASH 2022 annual meeting.

The first year after treatment yielded statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma

Second-line lisocabtagene maraleucel reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation.

Review some of our most-viewed coverage of advancements in cell therapies, including study data and clinical trial updates.

Annualized bleeding rates were superior with the gene therapy fidanacogene elaparvovec compared with factor IX treatment for patients with moderately severe to severe hemophilia B.

The CR was achieved at 1-month post-treatment.

Review some of our most-viewed coverage of advancements in gene therapies, including study data and clinical trial updates.

Crystal Mackall, MD, an Alliance for Cancer Gene Therapy scientist, is helping create a remote-control technology to personalize CAR T-cell therapy for each cancer patient.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed updated data from a study of NT-I7 and tisa-cel presented at ASH 2022.

Both REGENXBIO and Rocket Pharmaceuticals have announced trial updates in their gene therapy programs for rare diseases.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Invectys and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, announced the therapy and collaboration in June 2022.

Patients had an ORR of 83.8% with a median DOR of 15.7 months in data presented at the ASH 2022 meeting.

No dose-limiting toxicities or treatment-related serious adverse events were reported among 24 treated patients.

With several newly approved therapies hitting the market and an overflowing pipeline, the FDA has stepped in to help keep the burgeoning world of biotech on track.

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed new follow-up data from the HOPE-B study presented at ASH 2022.

The approval follows a CRL that was issued in 2021 due to problems with chemistry, manufacturing, and controls.

Review top news and interview highlights from the week ending December 16, 2022.

Half of wounds treated with the gene therapy had complete healing at both months 3 and 6 compared to 7% of placebo-treated wounds.

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed updated data presented at the ASH 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

New data from a phase 1/2 trial of BMS-986393 were presented at the 64th Annual ASH Meeting.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed new data from a phase 1/2 trial presented at ASH 2022.

Annualized bleed rate and FVIII infusion rates significantly decreased after infusion with the gene therapy.

Four of 17 patients who received UCART123v1.2 showed clinical benefit.

The professor at University Hospital Dresden discussed data presented at the 2022 ASH meeting.

The complete metabolic response rate was 70% 3 months after infusion.